226 related articles for article (PubMed ID: 26687972)
21. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
22. Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
Meadows SM; Conti MM; Gross L; Chambers NE; Avnor Y; Ostock CY; Lanza K; Bishop C
Mov Disord; 2018 Nov; 33(11):1740-1749. PubMed ID: 30485908
[TBL] [Abstract][Full Text] [Related]
23. (6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease.
Zhao R; Lu W; Fang X; Guo L; Yang Z; Ye N; Zhao J; Liu Z; Jia J; Zheng L; Zhao B; Zhang A; Zhen X
Pharmacol Biochem Behav; 2014 Sep; 124():204-10. PubMed ID: 24955866
[TBL] [Abstract][Full Text] [Related]
24. The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Buck K; Voehringer P; Ferger B
J Neurochem; 2010 Jan; 112(2):444-52. PubMed ID: 19895663
[TBL] [Abstract][Full Text] [Related]
25. Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: the effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine.
Czarnecka A; Lenda T; Domin H; Konieczny J; Smiałowska M; Lorenc-Koci E
Brain Res; 2013 Dec; 1541():92-105. PubMed ID: 24129225
[TBL] [Abstract][Full Text] [Related]
26. Neuronal firing activity and gene expression changes in the subthalamic nucleus after transplantation of dopamine neurons in hemiparkinsonian rats.
Rumpel R; Alam M; Klein A; Özer M; Wesemann M; Jin X; Krauss JK; Schwabe K; Ratzka A; Grothe C
Neurobiol Dis; 2013 Nov; 59():230-43. PubMed ID: 23938762
[TBL] [Abstract][Full Text] [Related]
27. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
Bishop C; Taylor JL; Kuhn DM; Eskow KL; Park JY; Walker PD
Eur J Neurosci; 2006 May; 23(10):2669-76. PubMed ID: 16817869
[TBL] [Abstract][Full Text] [Related]
28. Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats.
Mahmoudi J; Nayebi AM; Samini M; Reyhani-Rad S; Babapour V
Pharmacol Rep; 2011; 63(4):908-14. PubMed ID: 22001978
[TBL] [Abstract][Full Text] [Related]
29. The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.
Paquette MA; Foley K; Brudney EG; Meshul CK; Johnson SW; Berger SP
Psychopharmacology (Berl); 2009 Jul; 204(4):743-54. PubMed ID: 19283364
[TBL] [Abstract][Full Text] [Related]
30. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
[TBL] [Abstract][Full Text] [Related]
31. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Mo J; Zhang H; Yu LP; Sun PH; Jin GZ; Zhen X
Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801
[TBL] [Abstract][Full Text] [Related]
32. Deep brain stimulation of the pedunculopontine tegmental nucleus modulates neuronal hyperactivity and enhanced beta oscillatory activity of the subthalamic nucleus in the rat 6-hydroxydopamine model.
Alam M; Heissler HE; Schwabe K; Krauss JK
Exp Neurol; 2012 Jan; 233(1):233-42. PubMed ID: 22036687
[TBL] [Abstract][Full Text] [Related]
33. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
Iderberg H; Rylander D; Bimpisidis Z; Cenci MA
Exp Neurol; 2013 Dec; 250():116-24. PubMed ID: 24029003
[TBL] [Abstract][Full Text] [Related]
34. Neuronal activity in the medial associative-limbic and lateral motor part of the rat subthalamic nucleus and the effect of 6-hydroxydopamine-induced lesions of the dorsolateral striatum.
Lindemann C; Alam M; Krauss JK; Schwabe K
J Comp Neurol; 2013 Oct; 521(14):3226-40. PubMed ID: 23787707
[TBL] [Abstract][Full Text] [Related]
35. Dual effects of intermittent or continuous L-DOPA administration on gene expression in the globus pallidus and subthalamic nucleus of adult rats with a unilateral 6-OHDA lesion.
Nielsen KM; Soghomonian JJ
Synapse; 2003 Sep; 49(4):246-60. PubMed ID: 12827644
[TBL] [Abstract][Full Text] [Related]
36. Effect of the selective 5-HT
Frouni I; Kwan C; Bédard D; Belliveau S; Bourgeois-Cayer É; Gaudette F; Beaudry F; Hamadjida A; Huot P
Exp Brain Res; 2019 Jan; 237(1):29-36. PubMed ID: 30298296
[TBL] [Abstract][Full Text] [Related]
37. Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson's Disease.
Altwal F; Padovan-Neto FE; Ritger A; Steiner H; West AR
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641332
[TBL] [Abstract][Full Text] [Related]
38. Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
Xie CL; Wang WW; Zhang SF; Yuan ML; Che JY; Gan J; Song L; Yuan WE; Liu ZG
Sci Rep; 2014 Dec; 4():7506. PubMed ID: 25511986
[TBL] [Abstract][Full Text] [Related]
39. Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease.
Marin C; Bonastre M; Mengod G; Cortés R; Rodríguez-Oroz MC; Obeso JA
Exp Neurol; 2013 Dec; 250():304-12. PubMed ID: 24140562
[TBL] [Abstract][Full Text] [Related]
40. Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Pinna A; Costa G; Serra M; Contu L; Morelli M
Neuropharmacology; 2021 Sep; 196():108693. PubMed ID: 34229013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]